Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Research
Return to: PBR Home | Contract Research & Services | Contract Research | Suppliers

Review paper discussing the pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model; also touching on reMYND’s other proprietary transgenic mouse models (Tanghe et al., 2010).

Published 02 January 2013 | By reMYND

Notwithstanding the vast amount of resources invested into discovery and development of new targets and treatments, Alzheimer’s disease (AD) remains an indication with enormous unmet needs. One complicating factor for successful drug development is the unknown etiology of idiopathic AD. AD entails noxious aggregation of β-amyloid (Abeta) and Tau, representing fundamental processes in disease onset and progression

Available Downloads

Review paper discussing the pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model; also touching on reMYND’s other proprietary transgenic mouse models (Tanghe et al., 2010).